Literature DB >> 16568250

No loss of cardioprotection by postconditioning in connexin 43-deficient mice.

Gerd Heusch1, Astrid Büchert, Sandra Feldhaus, Rainer Schulz.   

Abstract

In situ hearts and isolated cardiomyocytes from heterozygous connexin 43-deficient (Cx43+/-) mice cannot be protected by ischemic preconditioning or diazoxide. We have now addressed the role of connexin 43 in ischemic postconditioning (PC). Wild type (WT) and Cx43+/- mice were subjected to 30 min coronary occlusion and 120 min reperfusion, with and without a PC protocol of three cycles of 10 s coronary occlusion/10 s reperfusion. Infarct size (TTC staining) was reduced by PC from 54+/-5 to 37+/-3% of area at risk in WT. Likewise, infarct size was reduced by PC from 53+/-4 to 34+/-3% of area at risk in Cx43+/-. We conclude that connexin 43 is no prerequisite for PC's protection. To this end, the signal transduction of ischemic preconditioning and postconditioning differs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16568250     DOI: 10.1007/s00395-006-0589-0

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  31 in total

1.  Subcellular preconditioning of stem cells: mito-Cx43 gene targeting is cytoprotective via shift of mitochondrial Bak and Bcl-xL balance.

Authors:  Gang Lu; Shujia Jiang; Muhammad Ashraf; Khawaja Husnain Haider
Journal:  Regen Med       Date:  2012-05       Impact factor: 3.806

2.  Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions <45 min.

Authors:  Xian-Liang Tang; Hiroshi Sato; Sumit Tiwari; Buddhadeb Dawn; Qiuli Bi; Qianhong Li; Gregg Shirk; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-06-30       Impact factor: 4.733

Review 3.  Connexins in the Heart: Regulation, Function and Involvement in Cardiac Disease.

Authors:  Antonio Rodríguez-Sinovas; Jose Antonio Sánchez; Laura Valls-Lacalle; Marta Consegal; Ignacio Ferreira-González
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

4.  Characterization of a critical role for CFTR chloride channels in cardioprotection against ischemia/reperfusion injury.

Authors:  Sunny Yang Xiang; Linda L Ye; Li-lu Marie Duan; Li-hui Liu; Zhi-dong Ge; John A Auchampach; Garrett J Gross; Dayue Darrel Duan
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

Review 5.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

Review 6.  What makes the mitochondria a killer? Can we condition them to be less destructive?

Authors:  Elizabeth Murphy; Charles Steenbergen
Journal:  Biochim Biophys Acta       Date:  2010-09-15

7.  Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice.

Authors:  Lei Xi; Anindita Das; Zhi-Qing Zhao; Vanessa F Merino; Michael Bader; Rakesh C Kukreja
Journal:  Circulation       Date:  2008-09-30       Impact factor: 29.690

8.  Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success.

Authors:  Michael V Cohen; Xi-Ming Yang; James M Downey
Journal:  Basic Res Cardiol       Date:  2008-07-14       Impact factor: 17.165

9.  Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice.

Authors:  Omar Bouhidel; Sandrine Pons; Richard Souktani; Roland Zini; Alain Berdeaux; Bijan Ghaleh
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

10.  The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs.

Authors:  Andreas Skyschally; Barbara Walter; Rie Schultz Hansen; Gerd Heusch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-02-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.